ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

Study Identifier:
D7890C00001
ClinicalTrials.gov Identifier:
NCT07037420
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Will Be Recruiting

Study Details

Medical Condition
  • Acromegaly
Study Drug
  • Drug: ALXN2420
  • Drug: Placebo
Date
Oct 2025 - Jan 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years
Requirements Information
Sex
Female & Male
Age
18 - 80 Years

Study Details

Medical Condition
  • Acromegaly
Study Drug
  • Drug: ALXN2420
  • Drug: Placebo
Date
Oct 2025 - Jan 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 80 Years years
Requirements Information

Protocol Summary

The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.

Trial Locations

No locations found.